

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN NO.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2020

Sr. No.	Particulars	(Rupees in Thousand)			
		Quarter Ended		Year Ended	
		30th June 2020	31st March 2020	30th June 2019	31st March 2020
		Unaudited	audited	Unaudited	Audited
I	Revenue from Operations	1,563	2,859	2,831	9,967
II	Other Income	1,563	2,859	2,831	9,967
III	Total Revenue (I + II)				
IV	Expenses				
	(1) Cost Materials consumed	-	-	-	-
	(2) Purchase of Stock-in-Trade	-	-	-	-
	(3) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	245	404	405	1,813
	(4) Employee Benefits Expenses	-	231	-	231
	(5) Depreciation and Amortisation Expenses	431	1,253	923	2,982
	(6) Administrative and Other Expenses	-	-	-	-
	(7) Finance Costs	676	1,888	1,328	5,026
	Total Expenses	887	971	1,503	4,941
V	Profit/(Loss) before Exceptional and Extra ordinary Items and tax (III - IV)				
VI	Exceptional Items	887	971	1,503	4,941
VII	Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI)				
VIII	Extra Ordinary Items	887	971	1,503	4,941
IX	Profit/(Loss) before Tax (VII-VIII)				
X	Tax Expenses	-	760	-	760
	(1) Current Tax	56	30	-	30
	(2) Tax Adjustment Previous Year	-	-	-	-
	(3) Deferred Tax	-	-	-	-
XI	Profit/(Loss) for the period from continuing operations (IX - X)	831	181	1,503	4,151
XII	Profit/(Loss) from discontinuing operations	-	-	-	-
XIII	Tax Expenses of discontinuing operations	-	-	-	-
XIV	Profit/(Loss) from discontinuing operations (after tax) (XII - XIII)	-	-	-	-
XV	Profit/(Loss) for the period (XI - XIV)	831	181	1,503	4,151
XVI	Other Comprehensive Income				
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
	B (i) Items that will not be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	831	181	1,503	4,151
XVIII	Earnings per Share :	0.55	0.12	1.00	2.77
	(1) Basic				
	(2) Diluted				

Notes :

- This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.
- The above Unaudited Financial Results for the Quarter Ended 30.06.2020 have been reviewed by the Audit Committee in their Meeting held on 18.08.2020 and approved by the Board of Directors of its Meeting held on 18.08.2020. The Limited Review Report of Auditors M/s VMD & Co. was also taken on record by the Board in its Meeting.
- The Company is not having any Subsidiary Company.
- The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.

For Chemo - Pharma Laboratories Limited

Ashok Somani

Ashok Somani
Director

Place : Mumbai

Date : 18th August, 2020



CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN NO.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

RECONCILIATION OF STANDLONE NET PROFIT FOR THE QUARTER ENDED 30TH JUNE, 2020

(Rs. In Thousand)

PARTICULARS	STANDLONE	
	UNAUDITED QUARTER ENDED 30.06.2020	AUDITED YEAR ENDED 31.03.2020
Reconciliation of Profit After Tax as reported earlier:		
Net Profit / (Loss) for the Period (as per AS)	831	4,151
Benefit / (Charge):	-	-
Impact of Deferred Income (Government Grant) Amortized to Income	-	-
Impact of Fair Valuation of Financial Instruments	-	-
Impact of Actuarial Gain / Loss Taken OCI	-	-
Impact of Adjustment of Deferred Tax	-	-
Net Profit / (Loss) for the Period (as per AS)	831	4,151

For Chemo Pharma Laboratories Ltd.



Ashok Somani
Director



Mumbai, 18th August, 2020